For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
Medical Marijuana, Inc. Reports $7.8 Million in Net Revenue in 2022 Second Quarter Financial and Operational Results – Medical Marijuana, Inc.
SAN DIEGO, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United